AZD-9291 | Osimertinib | Mereletinib CAS 1421373-65-0 AZD9291 longkanker Behandeling Active Pharma Ingrediënt Verkoopcontacten. Chemisch gebruik tegen kankergeneesmiddelenonderzoek alleen te koop. AZD-9291 Zuiverheid 99% available
AZD-9291 | Osimertinib | Mereletinib CAS 1421373-65-0
AZD-9291
Other Names: N(2{[2(diMethylaMino)ethyl](Methyl)eenMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]eenMino}fenyl)prop2enaMide;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indool-3-yl)-2-pyrimidinyl]amino]fenyl]-2-propenamide;AZD9291,AZD-9291
CAS: 1421373-65-0
MF: C28H33N7O2
Mw: 499.61 .
AZD 9291 is een onomkeerbare remmer van de epidermale groeifactorreceptor (EGFR) sensibiliserende en T790M-resistentiemutaties (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 en 16.2 μM, respectively). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.
